Skip to content
TrialScanner

NCT04832438

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Phase 2WithdrawnACTULead

Registry record

Lead sponsor
Actuate Therapeutics Inc.
Conditions
Salivary Gland Carcinoma; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Salivary Gland Neoplasms
Primary completion
Jun 18, 2033Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT04832438 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04832438: 9-ING-41 Plus Carboplatin in... | TrialScanner